Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Trial Profile

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABBV-321 (Primary)
  • Indications Bladder cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Sep 2019 Planned End Date changed from 29 Aug 2023 to 4 Sep 2025.
    • 05 Sep 2019 Planned primary completion date changed from 31 Aug 2021 to 7 Mar 2024.
    • 01 May 2019 Planned primary completion date changed from 1 Sep 2019 to 31 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top